Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia

Clinical trial NCT02104817 · COMPLETED

Trial details

NCT number: NCT02104817
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)

Start date: 2014-10-30
Primary completion: 2020-05-27
Enrollment: 13078

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.